Oridonin suppresses human gastric cancer growth in vitro and in vivo. - GreenMedInfo Summary
Oridonin Suppresses Human Gastric Cancer Growth in Vitro and in Vivo via Inhibition of VEGF, Integrinβ3, and PCNA.
Biol Pharm Bull. 2020 ;43(7):1035-1045. PMID: 32612067
The diterpenoid oridonin is an extract from the herb Rabdosia rubescens, commonly used in Traditional Chinese medicine. Oridonin has putative inhibitory activity in many human cancers. This study continued investigations into the therapeutic potential of oridonin against gastric carcinoma, and the underlying mechanism. An in vitro 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay with BGC823 cells was used to examine the cytotoxicity and apoptosis associated with oridonin treatment. RT-PCR and immunocytochemistry results showed evaluated levels of vascular endothelial growth factor (VEGF), cluster of differentiation 31 (CD31), integrinβ3, and proliferating cell nuclear antigen (PCNA) in BGC823 cells, or BGC823 xenografts nude mice. The inhibitory effect of oridonin was determined in vivo using the xenograft model, comparing tumor weight and volume, and calculating the tumor inhibition rate. The oridonin treatment and control groups were compared for associations between microvessel density and tumor inhibition rate, VEGF mRNA, integrin β3 mRNA, and PCNA protein. The ICs of oridonin at 12 and 72 h were 17.08 ± 2.38 and 8.76 ± 0.90 µg/mL, respectively. VEGF protein levels dramatically decreased in a time- and dose-dependent manner with oridonin treatment. BGC823 xenograft growth was notably less in the oridonin treatment groups, responding in a dose-dependent manner. After 14 d of treatment, VEGF, integrin β3, and PCNA levels were dramatically lower, and positively correlated with CD31 levels. Oridonin was associated with inhibition of BGC823 cell growth and tumor angiogenesis, in vitro and in vivo, in a dose-and-time dependent manner with lower levels of VEGF, integrin β3, and PCNA. Oridonin is a potential candidate agent for chemotherapy of gastric carcinoma.